Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer

被引：0
|
作者：
Oukkal, M. [1 ,2 ,3 ]
Kara, F. [1 ,2 ,3 ]
Difi, S. [1 ,2 ,3 ]
Bouzidi, D. [1 ,2 ,3 ]
Bentabak, K. [1 ,2 ,3 ]
Graba, A. [1 ,2 ,3 ]
Smail, N. [1 ,2 ,3 ]
Kaci, N. Ait [1 ,2 ,3 ]
Ahmed, R. Baba [1 ,2 ,3 ]
Bouzid, K. [1 ,2 ,3 ]
机构：
[1] Pierre & Marie Curie Ctr, Algiers, Algeria
[2] Mustapha Bacha Hosp, Algiers, Algeria
[3] Mohamed Lamine Dabaghine Hosp, Algiers, Algeria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15092
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus FOLFOX7 as first line treatment for patients (pts) with metastatic colorectal cancer: Preliminary results of a phase II study
    Oukkal, M.
    Salmi, K.
    Abed-Benmelha, N.
    Sefiane, S.
    Djeddi, H.
    Mahfouf, H.
    Bouzid, K.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII84 - VII84
  • [2] FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer
    Koca, Dogan
    Unal, Olcun Umit
    Oztop, Ilhan
    Yilmaz, Ugur
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2014, 25 (02): : 198 - 204
  • [3] Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)
    Oukkal, M.
    Djilat, K.
    Hadjam, R. M.
    Mahgoun, M. T.
    Bentabak, K.
    Graba, A.
    Smail, N.
    Kaci, N. Ait
    Ahmed, R. Baba
    Bouzid, K.
    [J]. BULLETIN DU CANCER, 2010, 97 (04) : 469 - 474
  • [4] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Hori, Natsuko
    Iwasa, Satoru
    Hashimoto, Hironobu
    Yanai, Takako
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Murakoshi, Kouji
    Yokote, Nobuaki
    Yamamoto, Hiroshi
    Shimada, Yasuhiro
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 435 - 438
  • [5] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Natsuko Hori
    Satoru Iwasa
    Hironobu Hashimoto
    Takako Yanai
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Kouji Murakoshi
    Nobuaki Yokote
    Hiroshi Yamamoto
    Yasuhiro Shimada
    [J]. International Journal of Clinical Oncology, 2013, 18 : 435 - 438
  • [6] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    [J]. ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [7] A phase III study of comparing FOLFOX plus /-bevacizumab with FOLFOX plus /-bevacizumab plus high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
    Wang, Feng
    Xiao, Jian
    Zhang, Yan-Qiao
    Yuan, Xianglin
    Fang, Weijia
    Wang, Wei
    Hu, Xiaohua
    Zhuang, Zhixiang
    Zhou, Fuxiang
    Ying, Jieer
    Yuan, Ying
    Guo, Zeng-qing
    Wu, XiangYuan
    Zou, Qing-Feng
    He, Ming-ming
    Guo, Ying
    Chen, Shuang-Zhen
    Xu, Rui-hua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
    Ehrenberg, Roland
    Halama, Niels
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [9] Analysis of oxaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the optimox study
    Buyse, Marc
    Quinaux, Emmanuel
    Abrahantes, Jose Cortiñas
    Tournigand, Christophe
    Cervantes, Andres
    Figer, Arie
    Andre, Thierry
    Tabah-Fisch, Isabelle
    De Gramont, Aimery
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 115 - 115
  • [10] Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence
    Bi, F.
    Li, Q.
    Zhou, C.
    Yu, J.
    Cai, X.
    Qiu, M.
    Liu, J.
    Yi, C.
    Luo, D.
    Xu, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345